重组人干扰素α2b联合复方异丙托溴铵在支气管哮喘合并病毒性肺炎患儿治疗中的应用

Application of Recombinant Human Interferonα2b Combined with Compound Ipratropium Bromide in the Treatment of Children with Bronchial Asthma Complicated with Viral Pneumonia

目的:分析重组人干扰素α2b联合复方异丙托溴铵治疗儿童支气管哮喘合并病毒性肺炎的临床效果。方法:选取某院2021年5月~2023年5月收治的140例支气管哮喘合并病毒性肺炎患儿为研究对象,采用随机数字表法分为对照组和观察组,每组70例。两组患儿均接受常规治疗,对照组在此基础上予以复方异丙托溴铵治疗,观察组在对照组基础上加用重组人干扰素α2b治疗,均连续治疗7天。治疗结束,比较两组患儿治疗总有效率和发热、肺部阴影、咳嗽、肺部啰音等症状的消失时间,记录患儿在治疗过程中是否发生不良反应。结果:治疗7天后,观察组治疗有效率(92.86%)高于对照组(72.86%,P<0.05);观察组退热、肺部阴影消失、咳嗽消失、肺部啰音消失等时间均短于对照组(P<0.05);两组患儿在用药治疗期间均没有出现不良反应。结论:重组人干扰素α2b联合复方异丙托溴铵治疗儿童支气管哮喘合并病毒性肺炎整体疗效较好,有助于主要症状较快缓解且不会增加不良反应发生风险。

Objective:To analyze the clinical efficacy of recombinant human interferonα2b combined with compound ipratropium bromide in the treatment of children with bronchial asthma complicated with viral pneumonia.Methods:A total of 140 children with bronchial asthma and viral pneumonia treated in a hospital from May 2021 to May 2023 were selected and divided into the control group and observation group by random number table method,with 70 patients in each group.Both groups were treated with conventional therapy,the control group was additionally treated with compound ipratropium bromide,and the observation group was additionally given recombinant human interferonα2b.The treatment continued for 7 days.After treatment,the total response rate and the time to disappearance of symptoms such as fever,pulmonary shadow,cough,and pulmonary rale were compared between the two groups,and the occurrence of adverse reactions during the treatment was recorded.Results:After 7 days of treatment,the response rate was higher in the observation group(92.86%)than that in the control group(72.86%,P<0.05).The time to fever clearance,disappearance of pulmonary shadow,improvement of cough and disappearance of lung rale in the observation group was shorter as compared with the control group(P<0.05).No adverse reactions occurred in either group during the treatment.Conclusion:Favorable overall efficacy was demonstrated with recombinant human interferonα2b combined with compound ipratropium bromide in the treatment of children with bronchial asthma complicated with viral pneumonia as it was conducive to rapid relief of main symptoms without additional risk of adverse reactions.